Carlos Danger, MD
Psychiatry · Miami, FLNPI 1508890153
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,605 of the $30,850 with a category attached, or 89.5%. AbbVie accounts for 95.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $12,963 and has fallen 99.8% since, to $26 in 2025. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $179.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$30K
- Teva Pharmaceuticals USA, Inc.$291
- Lundbeck LLC$259
- Takeda Pharmaceuticals U.S.A., Inc.$198
- Otsuka America Pharmaceutical, Inc.$116
- Indivior Inc.$99
- plus $292 from 6 others
Across 256 payments — averaging $8429.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.1M
- Janssen Research & Development, LLC$932K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$101K
- Sage Therapeutics, LLC$11K
- Avanir Pharmaceuticals, Inc.$4K
What the payments were for
- Speaking & faculty fees$27,60589%
- Travel & lodging$200%
- Food & beverage$3,14510%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 118 | $29,596 |
| Teva Pharmaceuticals USA, Inc. | 13 | $291 |
| Lundbeck LLC | 9 | $259 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $198 |
| Otsuka America Pharmaceutical, Inc. | 6 | $116 |
| Indivior Inc. | 4 | $99 |
| Johnson & Johnson | 4 | $94 |
| Alkermes, Inc. | 4 | $80 |
| Ironshore Pharmaceuticals Inc. | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$27,897
- VIIBRYD$200
- ABILIFY MAINTENA$107
How this compares
$30,850 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mirtazapine | 13 | $64 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Miami
- Kenny PerezMiami$453K
- Erik CabreraMiami$357K
- Miguel FloresMiami$176K
- Pedro RodriguezMiami$96K
- John NewcomerMiami$96K
- Patricia JunqueraMiami$80K
- Marc AgroninMiami$66K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.